Polyphenols from red wine modulate immune responsiveness: Biological and clinical significance

Current Pharmaceutical Design

Volumn 14, Issue 26, 2008, Pages 2733-2748

  Magrone, T ^a   Candore, G ^c   Caruso, C ^c   Jirillo, E ^a,b   Covelli, V ^d  

^a UNIVERSITY OF BARI   (Italy)

^b National Institute of Gastroenterology   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d POLICLINICO   (Italy)

Author keywords

Atherosclerosis; Cytokines; Immune system; Immunoglobulins; Nitric oxide; Polyphenols; Red wine

Indexed keywords

ALCOHOL; ANTHOCYANIN; B LYMPHOCYTE RECEPTOR; FLAVONOID; GAMMA INTERFERON; I KAPPA B ALPHA; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; LUTEOLIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE; POLYPHENOL DERIVATIVE; PROCYANIDIN; PROVINOLS TM; RESVERATROL; SIRTUIN 1; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALCOHOL CONSUMPTION; ALCOHOLIC BEVERAGE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL STIMULATION; CYTOKINE RELEASE; DIETARY INTAKE; DRUG STRUCTURE; ENZYME RELEASE; ENZYME SYNTHESIS; GASTROINTESTINAL ABSORPTION; GRAPE; HOST RESISTANCE; HUMAN; HYPERTENSION; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION PREVENTION; INNATE IMMUNITY; ISCHEMIC HEART DISEASE; LONGEVITY; MAXIMUM PLASMA CONCENTRATION; OXIDATIVE PHOSPHORYLATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RED WINE; REVIEW; RISK REDUCTION; THROMBOCYTE AGGREGATION;

ANIMALS; CHRONIC DISEASE; CORONARY DISEASE; CYTOKINES; FLAVONOIDS; HUMANS; IMMUNITY; IMMUNOGLOBULINS; LEUKOCYTES, MONONUCLEAR; NITRIC OXIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENOLS; WINE;

EID: 57349155877     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786264098     Document Type: Review

References (177)

1. Manach C, Mazur A, Scalbert A. Polyphenols and prevention of cardiovascular diseases. Curr Opin Lipid 2005; 16: 77-84.
2. Scalbert A, Johnson IT, Saltmarsh M. Polyphenols: Antioxidants and beyond. Am J Clin Nutr 2005; 81: S215-S217.
3. Cordova AC, Jackson LS, Berke-Schlessel DW, Sumpio BE. The cardiovascular protective effect of red wine. J Am Coll Surg 2005; 200: 428-39.
4. Bravo L. Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 1998; 56: 317-33.
5. Xiuzhen H, Tao S, Hongxiang L. Dietary polyphenols and their biological significance. Int J Mol Sci 2007; 8: 950-88.
6. Amorati R, Lucarini M, Mugnaini V, Pedulli GF, Roberti M, Pizzirani D. Antioxidant activity of hydroxystilbene derivatives in homogeneous solution. J Org Chem 2004; 69: 7101-7.
7. Baolin L, Inami Y, Tanaka H, Inagaki N, Iinuma M, Nagai H. Resveratrol inhibits the release of mediators from bone marrowderived mouse mast cells in vitro. Planta Med 2004;70: 305-9.
8. Bode AM, Dong Z. Targeting signal transduction pathways by chemopreventive agents. Mutat Res 2004; 555: 33-51.
9. Alarcon de la Lastra C, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications. Mol Nutr Food Res 2005; 9: 405-30.
10. Han Y, Zheng WH, Bastianetto S, Chabot JG, Quirion R. Neuro-protective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: Involvement of protein kinase C. Br J Pharmacol 2004; 141: 997-1005.
11. Hung LM, Chen JK, Huang SS, Lee RS, Su MJ. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 2000; 47: 549-55.
12. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006; 444: 868-74.
13. Zhu H, Guo Q, Mattson MP. Dietary restriction protects hippocampal neurons against the death-promoting action of a presenilin-1 mutation. Brain Res 1999; 842: 224-9.
14. Ingram DK, Weindruch R, Spangler EL, Freeman JR, Walford RL. Dietary restriction benefits learning and motor performance of aged mice. J Gerontol 1987; 42: 78-81.
15. Civitarese AE, Carling S, Heilbronn LK, Hulver MH, Ukropcova B, Deutsch WA, et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med 2007; 4: E 76.
16. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-42.
17. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-22.
18. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450: 712-6.
19. Liu L, Wang Y, Lam KSL, Xu A. Moderate wine consumption in the prevention of metabolic syndrome and its related medical complications. Endocr Metab Immune Disord Drug Targets 2008; 8: 89-98.
20. Oberdoerffer P, Sinclair DA. The role of nuclear architecture in genomic instability and ageing. Nat Rev Mol Cell Biol 2007; 8: 692-702.
21. Westphal CH, Dipp MA, Guarente L. A therapeutic role for sirtuins in diseases of aging? Trends Biochem Sci 2007; 32: 555-60.
22. Yamamoto H, Schoonjans K, Auwerx J. Sirtuin functions in health and disease. Mol Endocrinol 2007; 21: 1745-55.
23. Nisoli E, Clementi E, Carruba MO, Moncada S. Defective mitochondrial biogenesis: A hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res 2007; 100: 795-806.
24. Pecháová O, Rezzani R, Babál P, Bernátová I, Andriantsitohaina R. Beneficial effects of Provinols™: Cardiovascular system and kidney. Physiol Res 2006; 55: S17-S30.
25. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: Metaanalysis of effects on lipids and haemostatic factors. BMJ 1999; 319: 1523-8.
26. Renaud S, Guéguen R, Schenker J, d'Houtaud A. Alcohol and mortality in middle-aged men from eastern France. Epidemiology 1998; 9: 184-8.
27. Middleton E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000; 52: 673-751.
28. Zenebe W, Pecháová O. Effects of red wine polyphenolic compounds on the cardiovascular system. Bratisl Lek Listy 2002; 103: 159-65.
29. Curin Y, Andriantsitohaina R. Polyphenols as potential therapeutical agents against cardiovascular diseases. Pharmacol Rep 2005; 57: 97-107.
30. Jendeková L, Kojšová S, Andriantsitohaina R, Pecháňová O. The time-dependent effect of ProvinolsTM on brain NO synthase activity in L-NAME-induced hypertension. Physiol Res 2006; 55: S31-S37.
31. Iijima K, Yoshizumi M, Hashimoto M, Akishita M, Kozaki K, Ako J, et al. Red wine polyphenols inhibit vascular smooth muscle cell migration through two distinct signaling pathways. Circulation 2002; 105: 2404-10.
32. Di Carlo G, Mascolo N, Izzo AA, Capasso F. Flavonoids: Old and new aspects of a class of natural therapeutic drugs. Life Sci 1999; 65: 337-53.
33. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med 1999; 340: 115-26.
34. Yamashita S, Hirano K, Kuwasako T, Janabi M, Toyama Y, Ishigami M, et al. Physiological and pathologica roles of a multiligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. Mol Cell Biochem 2007; 299: 19-22.
35. Kuliczkowska-Płaksej J, Bednarek-Tupikowska G, Płaksej R, Filus A. Scavenger receptor CD36: Its expression, regulation, and role in the pathogenesis of atherosclerosis. Part I. Postepy Hig Med Dosw 2006; 60: 142-51.
36. Tabas I. Free cholesterol-induced cytotoxicity. A possible contributing factor to macrophage foam cell necrosis in advanced atherosclerotic lesions. Trends Cardiovasc Med 1997; 7: 256-63.
37. Sawayama Y, Tatsukawa M, Maeda S, Ohnishi H, Furusyo N, Hayashi J. Association of hyperhomocysteinemia and Chlamydia pneumoniae infection with carotid atherosclerosis and coronary artery disease in Japanese patients. J Infect Chemother 2008; 14: 232-7.
38. Watson C, Alp NJ. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci (Lond) 2008; 114: 509-31.
39. de Lorgeril M, Salen P. Wine ethanol, platelets, and Mediterranean diet. Lancet 1999; 353:1067.
40. Criqui MH, Ringel BL. Does diet or alcohol explain the French Paradox? Lancet 1994; 344: 1719-23.
41. Hertog MGL, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 1995; 155: 381-6.
42. Brouillard R, George F, Fougerousse A. Polyphenols produced during red wine ageing. Biofactors 1997; 6: 403-10.
43. Soulat T, Philippe C, Bal dit Sollier C, Brèzillon C, Berge N, Teissedre PL, et al. Wine constituents inhibit thrombosis but not atherogenesis in C57BL/6 apolipoprotein E-deficient mice. Br J Nutr 2006; 96: 290-8.
44. Demrow HS, Slane PR, Folts JD. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation 1995; 91: 1182-8.
45. De Curtis A, Murzilli S, Di Castelnuovo A, Rotilio D, Donati MB, De Gaetano G, et al. Alcohol-free red wine prevents arterial thrombosis in dietary-induced hypercholesterolemic rats: Experimental support for the 'French paradox'. J Thromb Haemost 2005; 3: 346-50.
46. Bell RA, Mayer-Davis EJ, Martin MA, D'Agostino RB Jr, Haffner SM. Associations between alcohol consumption and insulin sensitivity and cardiovascular disease risk factors: The insulin resistance and atherosclerosis study. Diabetes Care 2000; 23: 1630-6.
47. Ashen MD, Blumenthal RS. Clinical practice. Low HDL cholesterol levels. N Engl J Med 2005; 353: 1252-60.
48. Stocker R, O'Halloran RA. Dealcoholized red wine decreases atherosclerosis in apolipoprotein E gene-deficient mice independently of inhibition of lipid peroxidation in the artery wall. Am J Clin Nutr 2004; 79: 123-30.
49. Blanco-Colio LM, Valderrama M, Alvarez-Sala LA, Bustos C, Ortego M, Hernandez-Presa MA, et al. Red wine intake prevents nuclear factor-kappaB activation in peripheral blood mononuclear cells of healthy volunteers during postprandial lipemia. Circulation 2000; 102: 1020-6.
50. Shoji T, Masumoto S, Moriichi N, Akiyama H, Kanda T, Ohtake Y, et al. Apple procyanidin oligomers absorption in rats after oral administration: Analysis of procyanidins in plasma using the porter method and high performance liquid chromatography/tandem mass spectrometry. J Agric Food Chem 2006; 54: 884-92.
51. Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, et al. Reduced progression of atherosclerosis in apolipoprotein Edeficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol 1997; 17: 2744-52.
52. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen elderly study. Lancet 1993; 342: 1007-11.
53. Auger C, Gerain P, Laurent-Bichon F, Portet K, Bornet A, Caporiccio B, et al. Phenolics from commercialized grape extract prevent early atherosclerotic lesions in hamsters by mechanisms other than antioxidant effect. J Agric Food Chem 2004; 52: 5297-302.
54. Nardini M, Natella F, Scaccini C. Role of dietary polyphenols in platelet aggregation. A review of the supplementation studies. Platelets 2007; 18: 224-43.
55. Nam NH. Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 2006; 6: 945-51.
56. de Lange DW, van de Wiel A. Drink to prevent: Review on the cardioprotective mechanisms of alcohol and red wine polyphenols. Semin Vasc Med 2004; 4: 173-86.
57. Andriambeloson E, Magnier C, Haan-Archipoff G, Lobstein A, Anton R, Beretz A et al. Natural dietary polyphenolic compounds cause endothelial-dependent vasorelaxation in rat thoracic aorta. J Nutr 1998; 128: 2324-33.
58. Zenebe W, Pecháňová O, Andriantsitohaina R. Red wine polyphenols induce vasorelaxation by increased nitric oxide bioactivity. Physiol Res 2003; 52: 425-32.
59. Duarte J, Andriambeloson E, Diebolt M, Andriantsitohaina R. Wine polyphenols stimulate superoxide anion production to promote calcium signaling and endothelial-dependent vasodilatation. Physiol Res 2004; 53: 595-602.
60. Wallerath T, Poleo D, Li H, Forstermann U. Red wine increases the expression of human endothelial nitric oxide synthase: A mechanism that may contribute to its beneficial cardiovascular effects. J Am Coll Cardiol 2003; 41: 471-8.
61. Wollny T, Aiello L, Di Tommaso D, Bellavia V, Rotilio D, Donati MB, et al. Modulation of haemostatic function and prevention of experimental thrombosis by red wine in rats: A role for increased nitric oxide production. Br J Pharmacol 1999; 127: 747-55.
62. Pecháňová O, Bernátová I, Babál P, Martinez MC, Kyselá S, Štvrtina S, et al. Red wine polyphenols prevent cardiovascular alterations in L-NAME-induced hypertension. J Hypertens 2004; 22: 1551-9.
63. Bernátová I, Pecháňová O, Babál P, Kyselá S, Štvrtina S, Andriantsitohaina R. Wine polyphenols improve cardiovascular remodeling and vascular function in NO-deficient hypertension. Am J Physiol Heart Circ Physiol 2002; 282: H942-8.
64. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4.
65. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
66. Luscher TF. Endothelium-derived nitric oxide: The endogenous nitrosovasodilator in the human cardiovascular system. Eur Hearth J 1991; 12 Suppl E: 2-11.
67. Abbey M, Kerry NL. Flavonoids and their effects on LDL oxidation. Proc Nutr Soc Austr 1997; 21: 91-7.
68. da Luz PL, Serrano Junior CV, Chacra AP, Monteiro HP, Yoshida VM, Furtado M, et al. The effect of red wine on experimental atherosclerosis: Lipid-independent protection. Exp Mol Pathol 1999; 65: 150-9.
69. Coleman JW. Nitric oxide in immunity and inflammation. Int Immunopharm 2001; 1: 1397-406.
70. Bogdan C. Nitric oxide and the regulation of gene expression. Trends in Cell Biol 2001; 11: 66-75.
71. Nappi AJ, Vass E, Frey F, Carton Y. Nitric oxide involvement in Drosophila immunity. Nitric oxide 2000: 4: 423-30.
72. Klessig DF, Durner J, Noad R, Navarre DA, Wendehenne D, Kumar D, et al. Nitric oxide and salicylic acid signaling in plant defense. Proc Natl Acad Sci USA 2000; 97: 8849-55.
73. van der Veen RC. Nitric oxide and T helper cell immunity. Int Immunopharmacol 2001; 1: 1491-500.
74. Kronke KD, Fehsel K, Suschek C, Kolb-Bachofen V. Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival. Int Immunopharmacol 2001: 1: 1407-20.
75. Bogdan C, Rollinghoff M, Diefenbach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol 2000; 12: 64-76.
76. Thomassen MJ, Kavuru MS. Human alveolar macrophages and monocytes as a source and target for nitric oxide. Int Immunopharmacol 2001: 1: 1479-90.
77. Cifone MG, Ulisse S, Santoni A. Natural killer cells and nitric oxide. Int Immunopharmacol 2001; 1: 153-24.
78. Magrone T, Tafaro A, Jirillo F, Panaro MA, Cuzzuol P, Cuzzuol AC, et al. Red wine consumption and prevention of atherosclerosis: An in vitro model using human peripheral blood mononuclear cells. Curr Pharm Des 2007; 13: 3718-25.
79. Vogel RA. Vintners and vasodilators: Are French red wines more cardioprotective? J Am Coll Cardiol 2003; 41: 479-81.
80. Räthel TR, Samtleben R, Vollmar AM, Dirsch VM. Activation of endothelial nitric oxide synthase by red wine polyphenols impact of grape cultivars, growing area and the vinification process. J Hypertens 2007; 25: 541-9.
81. Wallerath T, Li H, Godtel-Ambrust U, Schwarz PM, Forstermann U. A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide 2005; 12: 97-104.
82. Caimi G, Carollo C, Lo Presti R. Wine and endothelial function. Drugs Exp Clin Res 2003; 29: 235-42.
83. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002; 106: 1652-8.
84. Magrone T, Panaro MA, Jirillo E, Covelli V. Molecular effects elicited in vitro by red wine on human healthy peripheral blood mononuclear cells: Potential therapeutical application of polyphenols to diet-related chronic disease. Curr Pharm Des 2008; 14(26): 2758-66.
85. Andriambeloson E, Kleschyov AL, Muller B, Beretz A, Stoclet JC, Andriantsitohaina R. Nitric oxide production and endotheliumdependent vasorelaxation induced by wine polyphenols in rat aorta. Br J Pharmacol 1997; 120: 1053-8.
86. Andriambeloson E, Stoclet JC, Andriantsitohaina R. Mechanism of endothelial nitric oxide-dependent vasorelaxation induced by wine polyphenols in rat thoracic aorta. J Cardiovasc Pharmacol 1999; 33: 248-54.
87. Ralay Ranaivo H, Dielbolt M, Andriantsitohaina R. Wine polyphenols induce hypotension, and decrease cardiac reactivity and infarct size in rats: Involvement of nitric oxide. Br J Pharmacol 2004; 142: 671-8.
88. Kwon KH, Murakami A, Tanaka T, Ohigashi H. Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulphate sodiuminduced experimental colitis in mice: Attenuation of proinflammatory gene expression. Biochem Pharmacol 2005; 69: 395-406.
89. Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001; 41: 492-9.
90. Erlund I, Kosonen T, Alfthan G, Maenpaa J, Perttunen K, Kenraali J, et al. Pharmacokinetics of quercetin from quercetin aglycone and rut in healthy volunteers. Eur J Clin Parmacol 2000; 56: 545-53.
91. Hollman PC, Bijsman MN, van Gameren Y, Cnossen EP, de Vries JH, Katan MB. The sugar moiety is a major determinant of the absorption of dietary flavonoids glycosides in man. Free Radic Res 1999; 31: 569-73.
92. Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-80.
93. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-7.
94. O'Neill LA. TLRs: Professor Mechnikov, sit on your hat. Trends Immunol 2004; 25: 687-93.
95. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
96. Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol 2003; 15: 396-401.
97. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
98. Dunne A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: Signal transduction during inflammation and host defense. Sci STKE 2003: 25 re3.
99. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, et al. Toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004; 303: 1522-6.
100. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410: 1099-103.
101. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
102. Rhee SH, Hwang D. Murine Toll-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF-κB and expression of the inducible cyclooxygenase. J Biol Chem 2000; 275: 34035-40.
103. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998; 282: 2085-8.
104. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004: 303: 1526-9.
105. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004: 303: 1529-31.
106. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001; 413: 732-8.
107. Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, Finberg RW, et al. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999; 274: 33419-25.
108. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor- 4 complex. J Immunol 2000; 164: 558-61.
109. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276: 10229-33.
110. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1: 398-401.
111. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 2001; 276: 16683-9.
112. Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001; 31: 2448-57.
113. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, et al. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 2003; 278: 37041-51.
114. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998; 9: 143-50.
115. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999; 11: 115-22.
116. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420: 329-33.
117. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420: 324-9.
118. McGettrick AF, O'Neill LA. The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction. Mol Immunol 2004; 41: 577-82.
119. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, et al. A. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2: 253-8.
120. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A. The human Toll signaling pathway: Divergence of nuclear factor kappa B and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 1998; 187: 2097-101.
121. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003; 300: 1524-5.
122. Karin M. The beginning of the end. IKB kinase (IKK) and NF-κB activation. J Biol Chem 1999; 274: 27339-42.
123. Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-34.
124. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5: 975-9.
125. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101: 10679-84.
126. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10: 416-21.
127. Jobin C, Sartor RB. The IκB/NF-κB system: A key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000; 278: C451-62.
128. Haller D, Jobin C. Interaction between resident luminal bacteria and the host: Can a healthy relationship turn sour? J Pediatr Gastroenterol Nutr 2004; 38: 123-36.
129. Kraehenbuhl JP, Corbett M. Immunology. Keeping the gut microflora at bay. Science 2004; 303: 1624-5.
130. Neish AS. The gut microflora and intestinal epithelial cells: A continuing dialogue. Microbes Infect 2002; 4: 309-17.
131. Kotanidou A, Xagorari A, Bagli E, Kitsanta P, Fotsis T, Papapetropoulos A, et al. Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice. Am J Resp Crit Care Med 2002; 165: 818-23.
132. Kim JS, Jobin C. The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signalling and gene expression by blocking IΚB kinase activity in intestinal epithelial cells and bonemarrow derived dendritic cells. Immunology 2005; 115: 375-87.
133. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-33.
134. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495-549.
135. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-κB signaling module. Oncogene 2006; 25: 6706-16.
136. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-8.
137. Malek S, Chen Y, Huxford T, Ghosh G. I kappa B beta, but not IκBα, functions as a classical cytoplasmic inhibitor of NF-κB dimers by masking both NF-kappaB nuclear localization sequences in resting cells. J Biol Chem 2001; 276: 45225-35.
138. Malek S, Huang DB, Huxford T, Ghosh S, Ghosh G. X-ray crystal structure of an IκBβ × NF-κB p65 homodimer complex. J Biol Chem 2003; 278: 23094-100.
139. Huang TT, Kudo N, Yoshida M, Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of I kappa B alpha controls cytoplasmic localization of inactive NF-κB/IκBα complexes. Proc Natl Acad Sci USA 2000; 97: 1014-9.
140. Renard P, Percherancier Y, Kroll M, Thomas D, Virelizier JL, Arenzana-Seisdedos F, et al. Inducible NF-κB activation is permitted by simultaneous degradation of nuclear IκBα. J Biol Chem 2000; 275: 15193-99.
141. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
142. Turpin P, Hay RT, Dargemont C. Characterization of IκBα nuclear import pathway. J Biol Chem 1999; 274: 6804-12.
143. Hayden MS, Ghosh S. Signaling to NF-κB. Genes & Dev 2004; 18: 2195-24.
144. Silverman N, Maniatis T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes & Dev 2001; 15: 2321-42.
145. Grimm S, Baeuerle PA. The inducible transcription factor NF-κB: structure-function relationship of its protein subunits. Biochem J 1993; 290: 297-308.
146. Henkel T, Machleidt T, Alkalay I, Krönke M, Ben-Neriah Y, Baeuerle PA. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-κB. Nature 1993; 365: 182-5.
147. Ritchie ME. Nuclear factor-κB is selectively and markedly activated in humans with unstable angina pectoris. Circulation 1998; 98: 1707-13.
148. Brand K, Page S, Rogler G, Bartsh A, Brandl R, Knuechel R, et al. Activated transcription factor nuclear factor-κB is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715-22.
149. Bourcier T, Sukhova G, Libby P. The nuclear factor-κB signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997; 272: 15817-24.
150. Ebenbichler CF, Kirchmair R, Egger C, Patsch JR. Postprandial state and atherosclerosis. Curr Opin Lipidol 1995; 6: 286-90.
151. Choi JS, Choi YJ, Park SH, Kang JS, Kang YH. Flavones mitigate tumor necrosis factor-alpha-induced adhesion molecule upregulation in cultured human endothelial cells: Role of nuclear factor-κB. J Nutr 2004; 134: 1013-9.
152. Hernandez-Presa MA, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95: 1532-41.
153. Schreck R, Meier B, Mannel DN, Droge W, Bauerle PA. Dithiocarbamates as potent inhibitors of nuclear factor-κB activation in intact cells. J Exp Med 1992; 175: 1181-94.
154. Feng AN, Chen YL, Chen YT, Ding YZ, Lin SJ. Red wine inhibits monocyte chemotactic protein-1 expression and modestly reduces neointimal hyperplasia after balloon injury in cholesterol-Fed rabbits. Circulation 1999; 100: 2254-9.
155. Xu R, Yokohama WH, Irving D, Rein D, Walzem RL, German JB. Effect of dietary catechin and vitamin E on aortic fatty streak accumulation in hypercholesterolemic hamsters. Atherosclerosis 1998; 137: 29-36.
156. Williams RJ, Motteram JM, Sharp CH, Gallagher PJ. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis 1992; 94: 153-9.
157. Iijima K, Yoshizumi M, Hashimoto M, Kim S, Eto M, Ako J, et al. Red wine polyphenols inhibit proliferation of vascular smooth muscle cells and downregulate expression of cyclin A gene. Circulation 2000; 101: 805-11.
158. Kerry NL, Abbey M. Red wine and fractioned phenolic compounds prepared from red wine inhibit low density lipoprotein oxidation in vitro. Atherosclerosis 1997; 135: 93-102.
159. Nigdikar SV, Williams NR, Griffin BA, Howard AN. Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo. Am J Clin Nutr 1998; 68: 258-65.
160. Goral J, Kovacs EJ. In vivo ethanol exposure down-regulates TLR2-, TLR4-, and TLR9-mediated macrophage inflammatory response by limiting p38 and ERK1/2 activation. J Immunol 2005; 174: 456-63.
161. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002: 298: 1911-2.
162. Davies RJ. Signal transduction to the nucleus by MAP kinase. In: Gutkind JS, Finkel T Eds. Signaling networks and cell cycle control: The molecular basis of cancer and other diseases. Humana Press Inc.: Totowa 2003: 153.
163. Aroor AR, Shukla SD. MAP kinase signalling in diverse effects of ethanol. Life Sci 2004; 74: 2339-64.
164. Arbabi S, Garcia I, Bauer GJ, Maier RV. Alcohol (ethanol) inhibits IL-8 and TNF: Role of the p38 pathway. J Immunol 1999; 162: 7441-5.
165. Kristof AS, Marks-Konczalik J, Moss J. Mitogen-activated protein kinases mediate activator Protein-1-dependent human inducible nitric-oxide synthase promoter activation. J Biol Chem 2001; 276: 8445-52.
166. Booyse FM, Pan W, Grenett HE, Parks DA, Darley-Husmar VM, Bradley KM, et al. Mechanism by which alcohol and wine polyphenols affect coronary heart disease risk. Ann Epidemiol 2007; 17: S24-31.
167. Magrone T, Tafaro A, Jirillo F, Amati L, Jirillo E, Covelli V. Elicitation of immune responsiveness against antigenic challenge in age-related disease: Effects of red wine polyphenols. Curr Pharm Des 2008; 14(26): 2749-57.
168. Lakoski SG, Liu Y, Brosnihan KB, Herrington DM. Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study. Atherosclerosis 2008; 197: 443-7.
169. Hollman PC, Bjsman MN, van Gameren Y, Cnossen EP, de Vries JH, Katan MB. The sugar moiety is a major determinant of the absorption of dietary flavonoids glycosides in man. Free Radic Res 1999; 31: 569-73.
170. Day AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJ, Morgan MR, et al. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosydase activity. FEBS Lett 1998; 436: 71-5.
171. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 2000; 130: S2073-85.
172. Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, Katan MB. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 1995; 62: 1276-82.
173. Stout RD, Suttles J. Immunosenescence and macrophage functional plasticity: Dysregulation of macrophage function by age-associated microenvironmental changes. Immunol Rev 2005; 205: 60-71.
174. Guruvayoorappan C, Kuttan G. (+)-Catechin inhibits tumor angiogenesis and regulates the production of nitric oxide and TNF-{α} in LPS-stimulated macrophages. Innate Immun 2008; 14, 160-74.
175. Cossarizza A. Apoptosis and HIV infection: About molecules and genes. Curr Pharm Des 2008; 14(3): 237-44.
176. Motilva V, Talero E, Calvo JR, Villegas I, Alarcon-de-la-Lastra C, Sanchez-Fidalgo S. Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities. Curr Pharm Des 2008; 14(1): 71-95.
177. O'Sullivan DJ. Genomics can advance the potential for probiotic cultures to improve liver and overall health. Curr Pharm Des 2008; 14(14): 1376-81.